Role of endoscopic retrograde cholangiopancreatography in the management of benign biliary strictures: What’s new?

Table 4 Prospective trials reporting placement of self-expandable metal stents in benign biliary strictures

Ref.	No. patients	Etiology	Type of stent	Clinical success (%)	Adverse events (%)	Migration rate (%)	Median follow-up
Park do et al[90]	33	CP, BDS, OLT, postsurgical	FCSEMS with 4 AF; FCSEMS with both FE	91 with AF; 88 with FE	3	0 with AF; 33 with FE	6 mo (IQR 4-6)
Wagh et al[82]	23	CP, BDS, OLT, idiopathic	Wallflex	96-short term 83-long term	4.3	39	18.8 mo (IQR 14.1-21.3)
Kahaleh et al[72]	133	CP, OLT	FCSEMS flared	67	3.1	10.5	95.5 ± 48.7 d
Devière et al[87]	187	CP, OLT, CCY	Wallflex	76.3	27.3	29.4	20.3 mo (IQR 12.9 -24.3)
Kaffes et al[65]	32	OLT	10 FCSEMS; 10 plastic stent	100 in FCSEMS; 80 in plastic stent	1 in FCSEMS, 5 in plastic stent	0 in FCSEMS	24.5 mo (range 4-38) in FCSEMS; 23 (range 1-42) in pastic stent
Haapamäki et al[70]	60	CP	30 FCSEMS; 30 plastic stent	92 in FCSEMS; 90 in plastic sten	29	10 in FCSEMS; 7 in plastic stent	40 mo (range-66)

AF: Anchoring fins; BDS: Bile duct stones; CCY: Cholecystectomy; CP: Chronic pancreatitis; FE: Fared ends; FCSEMS: Fully covered self-expandable metal stents; IQR: Interquartile range; OLT: Orthotic liver transplantation.